Sinew Pharma Inc.

Sinew Pharma Inc. is a biopharmaceutical company specializing in the development and research of innovative drugs targeting liver diseases and pain management. Its primary focus lies in creating treatments for non-alcoholic fatty liver conditions, particularly MASH (Metabolic dysfunction-associated steatohepatitis), and designing hepatotoxicity-free analgesic solutions. Key products under development include SNP-610 and SNP-630 for MASH, SNP-810—a liver-safe acetaminophen-based painkiller—and SNP-820, an antidote for acetaminophen poisoning. Many of these candidates are currently in advanced clinical trials, and the company is known for its proprietary technology platforms that address urgent unmet medical needs. Operating within the biotechnology and pharmaceutical research sector, Sinew Pharma Inc. contributes to advancing therapies for complex liver conditions and safer pain relief alternatives, reflecting its commitment to research excellence and improving patient outcomes in both local and global healthcare markets.